LINC00460 was observed to be significantly elevated in doxorubicin-resistant breast cancer cells, and LINC00460, together with FUS, promotes MYC expression by influencing the efficiency of intron removal during mRNA maturation. This evidence concerns the gene LINC00460 and breast cancer.